Molecular Partners to Regain Global Rights for MP0310 from Amgen
Details : MP0310 is a dual-targeted compound, targeting both FAP and 4-1BB, that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming to avoid systemic side effects associated with 4-1BB activation.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 26, 2022
Details : MP0310 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 08, 2019
Reset All
